BACKGROUND & AIMS: Mallory-Denk bodies (MDBs) are inclusions found in hepatocytes of patients with chronic liver diseases. Their clinical significance and prognostic value are not understood. METHODS: We performed cross-sectional and longitudinal analyses of patients with chronic hepatitis C (CHC) enrolled in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) trial to identify clinical features associated with MDBs and changes in MDBs over time. Biopsy specimens were obtained at baseline and 1.5 and 3.5 years after patients were assigned to groups for the HALT-C trial; and patients were followed up to assess clinical and histologic outcomes. RESULTS: Of biopsy samples collected from 1050 patients, MDBs were present in 15%. They were associated with insulin resistance and laboratory and histologic markers of advanced liver disease (higher levels of periportal fibrosis, pericellular fibrosis, steatosis, and inflammation). After adjusting for disease severity (the ratio of aspartate aminotransferase to alanine aminotransferase, albumin, platelets, fibrosis, steatosis), the presence of MDBs was associated with histologic progression (odds ratio, 1.97; P = .04). Of the 844 patients from whom serial biopsy samples were collected, 61 (7.2%) developed MDBs (MDB gain) and 101 (12.0%) lost MDBs (MDB loss). The presence or absence of diabetes mellitus was associated with MDB gain (P = .006) or loss (P = .024), respectively. Development of MDBs was associated with decompensation (adjusted hazard ratio, 2.81; P < .001) and histologic signs of progression (adjusted odds ratio, 4.02; P = .004). CONCLUSIONS: The presence of MDBs in liver biopsy samples from patients with CHC is associated independently with fibrosis progression. Gain of MDBs over time is associated with decompensation and progression to cirrhosis; and occurs most frequently among diabetic patients. MDBs might be used as prognostic factors for patients with CHC.
BACKGROUND & AIMS: Mallory-Denk bodies (MDBs) are inclusions found in hepatocytes of patients with chronic liver diseases. Their clinical significance and prognostic value are not understood. METHODS: We performed cross-sectional and longitudinal analyses of patients with chronic hepatitis C (CHC) enrolled in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) trial to identify clinical features associated with MDBs and changes in MDBs over time. Biopsy specimens were obtained at baseline and 1.5 and 3.5 years after patients were assigned to groups for the HALT-C trial; and patients were followed up to assess clinical and histologic outcomes. RESULTS: Of biopsy samples collected from 1050 patients, MDBs were present in 15%. They were associated with insulin resistance and laboratory and histologic markers of advanced liver disease (higher levels of periportal fibrosis, pericellular fibrosis, steatosis, and inflammation). After adjusting for disease severity (the ratio of aspartate aminotransferase to alanine aminotransferase, albumin, platelets, fibrosis, steatosis), the presence of MDBs was associated with histologic progression (odds ratio, 1.97; P = .04). Of the 844 patients from whom serial biopsy samples were collected, 61 (7.2%) developed MDBs (MDB gain) and 101 (12.0%) lost MDBs (MDB loss). The presence or absence of diabetes mellitus was associated with MDB gain (P = .006) or loss (P = .024), respectively. Development of MDBs was associated with decompensation (adjusted hazard ratio, 2.81; P < .001) and histologic signs of progression (adjusted odds ratio, 4.02; P = .004). CONCLUSIONS: The presence of MDBs in liver biopsy samples from patients with CHC is associated independently with fibrosis progression. Gain of MDBs over time is associated with decompensation and progression to cirrhosis; and occurs most frequently among diabeticpatients. MDBs might be used as prognostic factors for patients with CHC.
Authors: Anna S F Lok; Marc G Ghany; Zachary D Goodman; Elizabeth C Wright; Gregory T Everson; Richard K Sterling; James E Everhart; Karen L Lindsay; Herbert L Bonkovsky; Adrian M Di Bisceglie; William M Lee; Timothy R Morgan; Jules L Dienstag; Chihiro Morishima Journal: Hepatology Date: 2005-08 Impact factor: 17.425
Authors: Zobair M Younossi; Arthur J McCullough; Janus P Ong; David S Barnes; Anthony Post; Anthony Tavill; Diane Bringman; Lisa M Martin; Jennifer Assmann; Terry Gramlich; Kevin D Mullen; Robert O'Shea; William D Carey; Roy Ferguson Journal: J Clin Gastroenterol Date: 2004-09 Impact factor: 3.062
Authors: William M Lee; Jules L Dienstag; Karen L Lindsay; Anna S Lok; Herbert L Bonkovsky; Mitchell L Shiffman; Gregory T Everson; Adrian M Di Bisceglie; Timothy R Morgan; Marc G Ghany; Chihiro Morishima; Elizabeth C Wright; James E Everhart Journal: Control Clin Trials Date: 2004-10
Authors: Terry Gramlich; David E Kleiner; Arthur J McCullough; Christi A Matteoni; Navdeep Boparai; Zobair M Younossi Journal: Hum Pathol Date: 2004-02 Impact factor: 3.466
Authors: Raymond Kwan; Shinichiro Hanada; Masaru Harada; Pavel Strnad; Daniel H Li; M Bishr Omary Journal: FASEB J Date: 2012-02-23 Impact factor: 5.191
Authors: Amika Singla; David S Moons; Natasha T Snider; Elizabeth R Wagenmaker; V Bernadene Jayasundera; M Bishr Omary Journal: Hepatology Date: 2012-04-25 Impact factor: 17.425
Authors: Natasha T Snider; Nicholas W Griggs; Amika Singla; David S Moons; Sujith V W Weerasinghe; Anna S Lok; Chunhai Ruan; Charles F Burant; Hari S Conjeevaram; M Bishr Omary Journal: Hepatology Date: 2013-08-26 Impact factor: 17.425
Authors: Natasha T Snider; Sujith V W Weerasinghe; Amika Singla; Jessica M Leonard; Shinichiro Hanada; Philip C Andrews; Anna S Lok; M Bishr Omary Journal: J Cell Biol Date: 2011-10-17 Impact factor: 10.539
Authors: Kristin K Snow; Margaret C Bell; Anne M Stoddard; Teresa M Curto; Elizabeth C Wright; Jules L Dienstag Journal: Trials Date: 2014-05-07 Impact factor: 2.279